Medullary Thyroid Cancer: Clinical Trials

3 trials for Medullary Thyroid Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting, 1 unknown. 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 43Active not recruiting 1, Recruiting 1, Unknown 1

Follow Medullary Thyroid Cancer: new trials by email Literature Review of Medullary Thyroid Cancer trials Research Report on Medullary Thyroid Cancer

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Anlotinib Hydrochloride Capsule - Medullary Thyroid Cancer
Phase 4RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.3602023-06-192023-07-25
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg, Placebo tablet - Medullary Thyroid Cancer
Phase 4Active not recruitingExelixis2472015-02-252026-10-20
Radiolabeled Molecules for Medullary Thyroid Cancer
Lu 177 - Medullary Thyroid Cancer
Phase 4UnknownInstituto Nacional de Cancer, Brazil202013-08-012016-09-07

Narrower conditions

Carcinoma, Medullary (3)  ·  Thyroid Neoplasms (1)

Broader conditions

Adenocarcinoma (3)  ·  Carcinoma (3)  ·  Carcinoma, Neuroendocrine (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Neoplasms, Ductal, Lobular, and Medullary (3)  ·  Neoplasms, Germ Cell and Embryonal (3)  ·  Neoplasms, Glandular and Epithelial (3)  ·  Neoplasms, Nerve Tissue (3)  ·  Neuroectodermal Tumors (3)  ·  Neuroendocrine Tumors (3)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Head and Neck Neoplasms (1)  ·  Neoplasms by Site (1)

Interventions

Lutetium-177 (1)  ·  cabozantinib (1)

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Exelixis (1)  ·  Instituto Nacional de Cancer, Brazil (1)

Countries

Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  Croatia (1)  ·  France (1)  ·  Hungary (1)  ·  Israel (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Fernanda Vaisman, MD, PhD (1)

Results publications

PMID 35403447